Welcome to Shanghai Kuanta Biomedicine science and technology Co., Ltd. official website!

PRODUCTS 

pharmaceutical intermediates

Pesticide intermediates

NEWS 

Exploring the development of biopharmaceuticals 7 passionate collisions among domestic and overseas academicians

【Industrial Opinion of China Pharmaceutical Network】 Recently, seven academicians from home and abroad have held keynote speeches and thematic discussions to discuss the opportunities and paths for development of biopharmaceutical investment under the background of Guangdong, Hong Kong, and Macao Bay Area, and to discuss the topics of the biomedical industry. In the future, we will actively provide advice and suggestions for the development of biomedical industry in Pingshan District.


  

★Academician of the U.S. National Academy of Engineering——Cato T.Laurencin (Gatto Laurentson)

American Academy of Engineering, Medical School, Academician of the Third World Academy of Sciences, and Foreign Academician of the Chinese Academy of Engineering. He received a doctorate in medicine from Harvard University in 1987 and is a world-renowned expert in biomaterial science and engineering, orthopaedic surgeon, and founder of regeneration engineering.

“My research is mainly focused on the fields of regenerative cells and stem cells, hoping to be able to reprogram and use living cells and allow the wounded tissue to restore its existing functions. This technology has won international medicine known as the Oscar of the US medical community. prize.

Whether it is translational medicine or regenerative engineering, it is a new way of thinking that connects basic medical research with clinical treatment. Shenzhen has shown great motivation in this respect. The government is investing heavily in biomedical research and strives to become The leader in the global field, and various advantages and conditions of Pingshan, let me finally make a choice. ”

★ Academician of Chinese Academy of Engineering – Ding Jian

An oncologist, graduated from the National University of Kyushu, Japan, with a doctorate in 1992. He was elected a member of the Chinese Academy of Engineering in 2009 and is currently the dean of the College of Pharmacy of the Chinese Academy of Sciences.

"To truly innovate, we must pay attention to basic research. Shenzhen has been at the forefront of the country in this regard. For Pingshan, we can start with building a government-supported public platform to continuously improve various functions, including biological medicine and Basic tests of technology, as well as some large scientific research equipment, will enable companies to meet their various R&D needs in Pingshan, which will also help attract companies to settle down and help companies grow.”

★ Academician of the Chinese Academy of Sciences——Yan Deyue

Polymer chemist, professor at Shanghai Jiaotong University, received a Ph.D. in natural science from Leuven Catholic University in Belgium in 2002 and was elected as a member of the Chinese Academy of Sciences in 2005.

"Chemical treatment is currently the most effective method of treating cancer, but it also has some shortcomings and problems, such as easy to induce drug resistance, strong side effects, etc. For this reason we proposed the concept of small molecule nanomedicine and carried out animal experiments. With certain achievements, the next step is to strive for clinical progress as quickly as possible, hoping to establish a platform for transformation in Pingshan.”

★ Chinese Academy of Sciences Academician Zhang Xuemin

In 1995, he received a doctorate degree from the Academy of Military Medical Sciences. He has been the chief scientist of the National Major Scientific Research Plan Project, and the Academic Leader of the "Tumor Biology" Innovative Research Group of the National Development Fund Committee.

"Now there are no particularly effective drugs for some major diseases. We can only try to solve them through innovation. In this regard, Shenzhen has an obvious advantage. As Shenzhen continues to increase institutional innovation and improve its innovation policy, it cannot do anything else in other areas. If you are slow, you can get to the clinic in Shenzhen.”

★ Academician of the US National Academy of Engineering——Sun Yongkui

He went to California Institute of Technology in 1983 and received his Ph.D. in chemistry. He was awarded the British Chemical Engineers Association AstraZeneca Green Chemistry and Engineering Excellence Award, and the US President's Green Chemistry Challenge Award. In 2016, he was elected to the American Academy of Engineering.

“The development of new drugs requires a variety of basic science support and an excellent R&D ecological environment. I think that the R&D environment can be solved by establishing a large platform to shorten the time period, accelerate the development of new drugs, and attract innovative talents. Let them focus on their own development."

★ Academician of British Royal Society of Chemistry——Zhao Xiaobin

Ph.D. in Medical Materials, Institute of Polymer Research, Nankai University, Ph.D., Bioengineering Department, Biomaterials and Artificial Instruments, University of Strathclyde, UK. He is currently a member of the British Royal Society of Chemistry and a Chartered Chemist.

"The development of Pingshan National Biopharmaceutical Base can learn from Australia's practice and actively introduce quality projects from outside. This will not only reduce costs, but also increase the success rate after entering the market, thus accelerating the growth of the base."

★ Academician of French National Academy of Science and Technology - Han Zhongchao

He is a professor and doctoral tutor of Nankai University School of Medicine, and is the head of the Institute of Hematology of the Chinese Academy of Medical Sciences and the Chinese Academy of Medical Sciences. He was elected as a foreign academician of the French Academy of Medical Sciences in 2006.

"Stem cells and immune cells have opened up a new therapeutic approach or therapeutic approach, opening up a whole new therapeutic effect for some diseases that are now difficult for medical treatment. Stem cell regenerative medicine plus immune cells will be a revolution in medicine. With very large clinical application prospects, Pingshan should pay attention to the introduction of such scientific institutions and enterprises."

Original title: The collision of passion thoughts explores the future of biomedical industry

Add: Room 1610, No. 2, Lane 789, Tianzhu Road, Jiading New City, Shanghai, China

Contact: Manager Feng   Mobile:+86-13916443339 

E-mail:feng1150@aliyun.com

Zip code:201810

Tel:+86-21-69580854 Fax:+86-21-51062356

URL:www.kuantianpharm.com

Copyright(C)2018, Shanghai Kuanta Biomedical Technology Co., Ltd. All Rights Reserved. Supported by ChinaChemNet ChemNet Toocle Copyright Notice 备案字号:沪ICP备18023014号